IntellxxDNA

What IntellxxDNA does

IntellxxDNA is a privately held clinical decision support software company founded in 2015 and headquartered in Austin, Texas. The company provides genomic intelligence reports to licensed healthcare professionals practicing functional, integrative, and precision medicine, who order tests on behalf of patients with complex chronic conditions. IntellxxDNA itself does not operate a laboratory; buccal swab DNA collection kits are fulfilled by a partner laboratory and the company's value-add is software-based interpretation and clinical reporting rather than sample processing.

The core technology is a clinical decision support platform that analyzes single nucleotide polymorphisms (SNPs) using a proprietary analytical methodology examining gene-to-gene and gene-to-environment interactions. Reports cover over 700 SNPs with more than 10,000 peer-reviewed references and are organized into condition-specific modules: Cognition & Memory (500+ variants), Medical Overview (300+ variants), Mental Wellness (250+ variants), Neurodevelopmental (autism, ADHD, PANDAS/PANS), Spotlight on Anxiety & Depression (40+ SNPs, launched October 2024), and Women's Health (250+ variants across 21 topics including PCOS, endometriosis and fertility, launched May 2025).

Revenue is generated through a B2B clinician portal where licensed providers create accounts, order reports per patient, and access training and customer support. Reports are cash-pay and not covered by insurance. The go-to-market combines clinician-led direct sales with thought leadership via podcasts, webinars, peer-reviewed publications, and a public-facing "Find a Provider" directory that funnels patients to enrolled clinicians. The company is founder-owned, with co-founders Dr. Sharon Hausman-Cohen (Harvard-trained, board-certified in Family and Integrative Medicine) as Chief Science Officer and Carol Bilich as CEO; the team is approximately 51-100 people.

Name

IntellxxDNA

Legal name

IntellxxDNA, LLC

Website

https://intellxxdna.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

IntellxxDNA is a clinical decision support software company that provides SNP-based genomic reports (700+ variants, 10,000+ references) to licensed functional and integrative medicine clinicians for personalized treatment of chronic conditions.

Ownership category

akta.pro rank

Product category

Clinical Decision Support Software

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Health Services (8000)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Population Genomics & Preventive Precision Health Programs (HLAAANAL)

Keywords

• Clinical decision support software
• Genomic intelligence platform
• SNP analysis software
• Precision medicine genomics
• Functional medicine reporting

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Genomic Testing Reports: IntellxxDNA provides clinical decision support software and genomic intelligence reports to licensed healthcare professionals who order tests on behalf of their patients. The company is not a laboratory and does not perform laboratory services. DNA collection uses buccal swab kits shipped from a partner laboratory when clinicians order reports through the clinician portal.
2. Clinician Account Access: Licensed healthcare professionals create accounts to access the platform for patient reporting, training materials, and support. Clinicians pay for report access when ordering for patients.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

IntellxxDNA provides a Clinical Decision Support Software platform that analyzes over 700 single nucleotide polymorphisms (SNPs) with more than 10,000 peer-reviewed references to produce condition-specific genomic reports for licensed healthcare professionals. The platform's proprietary methodology examines gene-to-gene and gene-to-environment interactions, delivering color-coded, actionable reports that pair genetic findings with evidence-based intervention strategies in environment, lifestyle, nutrition, supplements, and medications. Reports are exclusively ordered by licensed clinicians through the clinician portal on behalf of their patients, with DNA collected via buccal swab kits shipped from a partner laboratory.

Differentiator

Problem solved

Functional benefit

Brands

• IntellxxDNA Clinical Decision Support Platform: A proprietary genomic research and intelligence platform providing comprehensive, accessible medical reporting and scientific explanations of individual patient gene functions.

Products and services

• IntellxxDNA Clinical Decision Support Platform Proprietary genomic research and intelligence platform providing comprehensive, accessible medical reporting and scientific explanations of individual patient gene functions for licensed healthcare professionals. Analyzes over 700 SNPs with more than 10,000 references and delivers color-coded, clinically organized reports with evidence-based intervention recommendations across environment, lifestyle, nutrition, supplements, and medications.
• Cognition & Memory Report Genomic report analyzing over 500 clinically significant gene variants within 21 organized topics to optimize cognition, memory, and brain health, including reversible causes of memory loss from brain fog to dementia, covering brain inflammation, blood-brain barrier permeability, brain ischemia, brain nutrient panels, detoxification, hormones, homocysteine and methylation, and mitochondrial factors.
• Medical Overview Report Comprehensive genomic report analyzing over 300 clinically significant gene variants across 20 organized topics covering anesthesia response, blood clots, cardiac disease, diabetes, gluten/dairy/histamine tolerance, methylation, nutrition, detox, macular degeneration, melanoma, obesity, and thyroid function.
• Mental Wellness Report Genomic report analyzing over 250 clinically significant gene variants within 20 organized topics focused on brain neurotransmitters, mental performance, attention, focus, stress response, and addiction for mental wellness optimization.
• Neurodevelopmental Report Comprehensive report combining the Mental Wellness Report with supplementary neurodevelopmental panels covering glutamate, neural connectivity, GABA receptors, mitochondrial factors, and cell signaling, designed for individuals with autism spectrum disorder, PANS/PANDAS, ADHD, and OCD.
• Women's Health Report Genomic report analyzing over 250 clinically significant gene variants across 21 organized topics addressing fertility challenges, hormone imbalances, PCOS, endometriosis, vasomotor symptoms, and reproductive wellness for women's health.
• Spotlight on Anxiety & Depression Report Focused genomic report analyzing over 40 clinically significant SNPs that influence serotonin, adrenaline, norepinephrine, dopamine, cortisol, brain histamine, and other mental health-related pathways to support anxiety and depression treatment.
• Executive Combination Report Combined package bundling the Cognition & Memory Report and Medical Overview Report to provide comprehensive genomic analysis across cognitive and general health domains for licensed clinicians.

Quantifiable outcome

• A child's IQ improved from 54 to 70 after genomically-targeted treatment
• +4 more outcomes

Named customers11 records

Segments5 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

Partnerships

Two partnerships are on record, tiered core.

• IRB-Approved Memory and Genomics StudycoreStrategic or Co-development Partner · 17 October 2023IntellxxDNA's innovative memory and genomics decision-making tool study gained IRB (Institutional Review Board) approval, indicating rigorous research methodology and ethical oversight for clinical research.
• Documenting HopecoreStrategic or Co-development Partner · 5 October 2023Documenting Hope is the research arm of Epidemic Answers, a 501(c)(3) nonprofit dedicated to helping children heal from chronic health conditions. IntellxxDNA announced a partnership to power a groundbreaking child health study, providing genomic analysis capabilities for research into chronic conditions affecting children.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Viome: Viome combines genetic and microbiome analysis to deliver personalized nutrition and wellness recommendations. Comparable as a multi-omics precision health platform targeting health-conscious consumers with intervention-focused reports.
• Genomind: Genomind provides pharmacogenomic clinical decision support for mental health clinicians, including the Genecept Assay. Highly comparable as a genetic test interpretation platform sold exclusively through licensed healthcare professionals.
• SelfDecode: SelfDecode offers DNA analysis reports covering health traits, wellness optimization, and chronic condition risk — using polygenic scoring and SNP analysis similar to IntellxxDNA's methodology, with comparable depth of variant coverage.
• DNAfit: DNAfit provides genetic-based fitness, nutrition, and wellness reports with SNP-driven intervention recommendations. Comparable DNA analysis approach targeting health optimization and personalized lifestyle interventions.
• InsideTracker: InsideTracker integrates DNA analysis with blood biomarkers to provide personalized health and longevity recommendations. Comparable business model delivering genomics-based wellness insights through both clinicians and direct consumers.

Broad incumbents

• GeneDx: GeneDx is a clinical genetic testing laboratory serving healthcare providers with diagnostic genetic testing and interpretation. A broader incumbent in the genomics-for-clinicians space, though focused more on rare disease diagnostics than chronic condition management.
• Tempus: Tempus is a large precision medicine company combining genomic sequencing with clinical decision support for oncology and other conditions. A well-capitalized incumbent moving into multi-specialty precision medicine with clinician-facing interpretation tools.
• 23andMe: 23andMe is a much larger direct-to-consumer genetic testing company that provides health and ancestry reports. While serving a broader consumer market, it overlaps with IntellxxDNA in genetic-based health insights, though without the clinical decision support positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/intellxxdna
• LinkedInlinkedin.com/company/intellxxdna
• Instagraminstagram.com/intellxxdna
• Xx.com/intellxxdna

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IntellxxDNA